skip to Main Content

Dr. Bekaii-Saab on the APACT Trial in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses the implications of the randomized phase III APACT trial (NCT01964430) evaluating gemcitabine alone versus gemcitabine plus nab-paclitaxel (Abraxane) as adjuvant therapy in patients with pancreatic cancer.

Watch here . . . 

Back To Top